Investor Presentaiton

Continued strong development in free cash flow during the Strive25 strategy period Taxation Reported tax rate Net working capital Net working capital, % of revenue CAPEX² CAPEX DKKM Depreciation and amortisation, % of revenue CAPEX, % of revenue 5% 5% 5% 6% 5% 4% 4%- 4% 5% 4% 4% 25% 26% 4% 23% 23% 23% 23% -23% 24% 23% 24% -24% 931 1,016 1,135 21% 636 566 18/191 19/20 20/21 21/22 YTD 22/23 Long term 18/19 19/20 20/21 21/22 YTD 22/23 Long term 18/19 19/20 20/21 21/22 YTD 22/23 Long term • • DK statutory corporate tax rate lowered to 22% in 2016. Coloplast pays the majority of its tax in Denmark Coloplast tax rate expected to be -23% for the Strive25 strategy period FY 22/23 tax rate expected around 21% due to positive impact from Atos Medical IP transfer • Long-term Net working capital expected to be stable at -24%, impacted by: o Growth in mature markets • Growth in Emerging markets which have long credit times o Increasing inventory levels on strategic raw materials and products H1 22/23 NWC-to-sales impacted mainly by increased inventories, as well as timing of trade payables. FY 22/23 expected at around 24% • CAPEX-to-sales expected to be 4-6% in Strive25 Continued investments in machines & capacity expansion Widening & diversifying manufacturing footprint: volume sites in Costa Rica became operational in 20/21 & 21/22 GOP5 investments - automation in Hungary and China IT investments and sustainability investments Atos CAPEX integration costs of up to DKK 150 million split over 21/22-23/24 (vast majority will be IT CAPEX) Full year impact of -DKK 230 million of amortisation related to the Atos Medical acquisition in 22/23 1 Impacted by provision for Mesh litigation 42 2 Gross investments in PPE & intangibles, excluding acquisitions Coloplast

View entire presentation